Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
Status:
Terminated
Trial end date:
2020-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600
mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease
who show symptoms of active inflammation despite being on ongoing treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.